Aerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE